Moderna Stock News

Moderna Inc. executives said on Thursday they believe a fourth COVID-19 vaccine shot will be needed late this year due to waning protection from earlier doses, which could push up sales in the second half of 2022. Chief Executive Stephane Bancel stressed that the company’s current sales projections for its Spikevax COVID-19 shot—$19 billion in […]

The approval gives people who are hesitant to take currently available vaccines made by Pfizer Inc., AstraZeneca Plc and Moderna Inc. another option.

Covid-19 vaccine: The approval gives people who are hesitant to take currently available vaccines made by Pfizer Inc., AstraZeneca Plc and Moderna Inc. another option

Moderna executives said on Thursday, February 24, they believe a fourth COVID-19 vaccine shot will be needed late this year due to waning protection from earlier doses, which could push up sales in the second half of 2022. Chief executive Stephane Bancel stressed that the company’s current sales projections for its Spikevax COVID-19 shot – $19 billion in 2022, up from its prior estimate of $18.5 billion – does not include any additional sales to the United States this year. “What is not clear today is what will the US government decide to do for 2022. Will it be a private market, or a mix of private and free vaccines,” Bancel said. The company said it was in talks with countries for more vaccine orders this year. Moderna shares jumped 11% to $150.80 amid a fall in the broader markets on Thursday. The stock was down over 70% from its August peak over lackluster flu vaccine data and questions of long-term sustainability of COVID-19 vaccine sales. However, the company sees a need for seasonal boosters to shore up immunity in people at high risk of severe illness as the virus continues to circulate while putting less of a strain on healthcare systems. “We do believe that we are transitioning into an endemic phase, marked by a period of stability in case counts, hospitalizations, and death, at least in the Northern Hemisphere,” said Moderna’s chief medical officer Paul Burton.

Moderna raised its expectations based on current advance purchase agreements with governments around the world.

Moderna, Inc. (NASDAQ: MRNA ) reported better-than-expected fourth-quarter earnings Thursday and announced a slight upward revision to its vaccine sales forecast for 2022. The company also announced a $3-billion stock buyback. The stock rallied 15.1% in Thursday''s trading session. Here''s what two analysts had to say about the earnings results. The Moderna Analysts: Needham analyst Joseph Stringer maintained a Hold rating on Moderna. SVB Leerink analyst Mani Foroohar has an Underperform rating. Vaccine Expectations Fully Priced In, Needham Says: Moderna''s fourth-quarter sales comprised $700 million from the U.S., equating to 45 million doses, and $6.1 billion from outside of the U.S., equivalent to 252 million doses, Stringer said. The company said it''s in active talks globally for additional Spikevax advance purchase agreements, or APA, in 2022, the analyst noted. Sales will likely be higher in the second half relative to the first half due to the Northern Hemisphere entering fall/winter booster season and due to an expected shift to a COVID endemic phase, he added.

U.S. indices finished higher as stocks sharply rebounded after falling following the Russian invasion of Ukraine . The Nasdaq composite finished higher by 3.34% to 13,473; The Invesco QQQ Trust Series 1 (NASDAQ: QQQ ) gained 3.36% to $340.49 The S&P 500 traded higher by 1.50% to 4,288; The SPDR S&P 500 ETF Trust (NASDAQ: SPY ) gained 1.50% to $428.30 The Dow Jones composite traded higher by 0.79% to 11,179; The SPDR Dow Jones Industrial Average ETF Trust (NASDAQ: DIA ) finished higher by 0.25% to $332.34 Here are the day''s winners and losers from the … Full story available on Benzinga.com

News of Russia''s full-scale invasion of Ukraine sent stocks plummeting out of the gate today. SEE MORE 10 Biggest Losers in the S&P 500 This Year "We''re clearly in risk-off mode in the market right now given the uncertainty regarding the military operations in Ukraine," says Brian Price, head of investment management for Commonwealth Financial Network. "There seems to be some element of surprise that the events have escalated so quickly and I would expect that we''ll continue to see volatility in the near term." Indeed, after the Dow Jones Industrial Average flirted with correction territory and the Nasdaq Composite slipped below its bear-market level on an intraday basis, the major market indexes reversed course as President Joe Biden announced a new round of sanctions against Russia, including freezing trillions of dollars in Russian assets, and said he is sending additional U.S. troops to Eastern European countries that are in NATO. Sign up for Kiplinger''s FREE Investing Weekly e-letter for stock, ETF and mutual fund recommendations, and other investing advice.

MRNA earnings call for the period ending December 31, 2021.

Major stock markets in the United States turned to positive territory at Thursday''s closing bell, with the Nasdaq 100 leading the rally by surging nearly 3.5%. Moderna''s shares jumped by over…

U.S. Biotech Company Moderna has continues to reap the rewards of its COVID-19 vaccine. In the final quarter of 2021, the company had achieved net The post Moderna announces $4.9bn in profits, raises 2022 forecast appeared first on Vanguard News .

U.S. stocks pared some earlier losses toward the end trading, with the Nasdaq jumping 2% on Thursday. US President Biden, during his press briefing on Ukraine/Russia, said he has authorized additional US military deployments today after Russia’s President Vladimir Putin announced that the country’s armed forces would carry out a “special military operation” in Ukraine. The Dow traded down 0.66% to 32,912.79 while the NASDAQ rose 2% to 13,298.18. The S&P also rose, gaining, 0.35% to 4,240.12. Check out this: Insiders Buy More Than $170M Of 4 Stocks Leading and Lagging Sectors Communication services shares climbed by 0.9% on Thursday. Meanwhile, top gainers in the sector included Globalstar, Inc. (NYSE: GSAT ), up 17% and Tremor International Ltd (NASDAQ: TRMR ) up 13%. In trading on Thursday, financials shares dipped 3.4%. Top Headline Moderna, Inc. (NASDAQ: MRNA ) reported better-than-expected results for its fourth quarter and announces a new $3 billion buyback program. Moderna posted quarterly earnings of $11.29 per share, beating analysts’ estimates of $9.90 per share.

The European Union''s health regulator on Thursday (Feb 24) backed giving a booster shot of Pfizer and BioNTech''s COVID-19 vaccine to adolescents aged 12 and over, as well as the expanded use of Moderna''s shot in children ages six to 11. The recommendations by the European Medicine Agency''s (EMA) Committee

The European Union''s drug watchdog Thursday approved Moderna''s anti-Covid shot for children aged six to 11, the second vaccine to be approved for younger children in the 27-member bloc.

Moderna projects $19 billion in revenue in 2022 off of sales of its COVID-19 vaccine alone, as the shot remains a cash-cow for pharmaceutical giants who won the race to get the shot.